Otros idiomas ORION Corp.

Acciones

A271560

KR7271560005

Precio de cierre Korea S.E. Otros sitios de cotización 00:00:00 16/05/2024			Varia. Cinco días.	Varia. 1 de enero.
92.400 ^KRW	+1,20 %		-0,32 %	-20,41 %

13/03	ORION Corp. informa de los resultados del año completo que finalizó el 31 de diciembre de 2023	CI
2023	ORION Corp. informa de los resultados del tercer trimestre y los nueve meses finalizados el 30 de septiembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

ORION Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Orion Set to Acquire 25% Stake in LegoChem Biosciences	17/01
Orion Temporarily Resumes Production of Discontinued Snacks to Offer Young Patients	10/01
ORION Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Celcuity to Proceed With Phase 1b/2 Trial of Gedatolisib Plus Nubeqa, Signs Supply Agreement With Bayer	22/08/23
ORION Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Marinus Pharmaceuticals Says European Commission Approves Ztalmy Oral Suspension	31/07/23
Orion Corporation Announces European Commission Approval of Ztalmy(R) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder	31/07/23
ORION Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
EU empfiehlt weitere Indikation für Bayer-Krebsmittel Nubeqa	27/01/23
Orion Corporation and Amneal Pharmaceuticals, Inc. Sign License Agreement with Amneal Pharmaceuticals, Inc. to Commercialise Amneal's Generic Products in Europe, Australia and New Zealand	04/01/23
South Korean Snack Maker Orion Temporarily Closes Tmall Flagship Store	27/12/22
FDA prüft neue Indikation für Bayer-Krebsmittel Nubeqa beschleunigt	03/05/22
Orion Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU	18/02/22
Infosys Selected by Finland-Based Orion to Help Transform Its ERP, Planning Platforms	14/12/21
Orion's Net Attributable Income Declines 4.3% in September Quarter	11/11/21
Marinus Pharmaceuticals Submits NDA to FDA for Seizure Treatment	03/08/21
China's Economy Powers Ahead While the Rest of the World Reels	13/01/21
Les actions hésitantes, la Chine et les résultats en soutien	09/07/20
Lotus Pharma and Orion to Enter into Marketing and Distribution Agreement	31/12/19

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas ORION Corp.

Acciones

A271560

KR7271560005

Otros idiomas

Filtros